Search Result

Results for "

Porphyria

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cytochrome P450 (3) Endogenous Metabolite (5) Environmental Pollutants (1) Herbicide (4) Isotope-Labeled Compounds (1) LYTACs (1) Reference Standards (2) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Metabolic Disease (10) Neurological Disease (3)
Oligonucleotides:	siRNA drugs (3) siRNAs (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-137808

Succinyl-Coenzyme A sodium 3 Publications Verification Succinyl-CoA sodium	Endogenous Metabolite	Neurological Disease Metabolic Disease
Succinyl CoA (Succinyl-coenzyme A) sodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA sodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA sodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA sodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .

HY-W040030

Hematin 1 Publications Verification	Cytochrome P450	Metabolic Disease Cancer
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .

HY-132610A

Givosiran sodium 1 Publications Verification ALN-AS1 sodium	Small Interfering RNA (siRNA)	Metabolic Disease
Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP) .

HY-132610

Givosiran 1 Publications Verification ALN-AS1	Small Interfering RNA (siRNA)	Metabolic Disease
Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP) .

HY-B1880

Oxadiazon	Environmental Pollutants Cytochrome P450 Herbicide	Neurological Disease Metabolic Disease
Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .

HY-113318

Coproporphyrin I	Endogenous Metabolite	Metabolic Disease
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

HY-W653982

Coproporphyrin I-15N4	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Coproporphyrin I- ¹⁵N₄ is a ¹⁵N-labeled Coproporphyrin I (HY-113318). Coproporphyrin I is an endogenous metabolite present in urine and blood that can be used for the research of liver disease and porphyria .

HY-150151A

GalNac-siRNA negative control (21nt)	LYTACs	Cardiovascular Disease
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

HY-148285

Succinyl CoA Succinyl-coenzyme A; S-(Hydrogen succinyl)coenzyme A	Endogenous Metabolite	Metabolic Disease
Succinyl CoA (Succinyl-coenzyme A) is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .

HY-B1880R

Oxadiazon (Standard)	Herbicide Reference Standards Cytochrome P450	Neurological Disease Metabolic Disease
Oxadiazon (Standard) is the analytical standard of Oxadiazon (HY-B1880). This product is intended for research and analytical applications. Oxadiazon is an orally active herbicide. Oxadiazon reduces hepatic cytochrome P450 levels. Oxadiazon increases palmitoyl CoA oxidase, acetyl carnitine transferase, and hepatic ALAS activity. Oxadiazon induces hepatomegaly and experimental porphyria. Oxadiazon controls weeds. Oxadiazon may be used in neurodegenerative disease research .

HY-12464

Butafenacil WC-9717; CGA-276854	Herbicide	Others
Butafenacil (WC-9717; CGA-276854) is an herbicide that inhibits protoporphyrinogen oxidase .

HY-12464R

Butafenacil (Standard) WC-9717 (Standard); CGA-276854 (Standard)	Herbicide Reference Standards	Others
Butafenacil (Standard) is the analytical standard of Butafenacil. This product is intended for research and analytical applications. Butafenacil (WC-9717; CGA-276854) is an herbicide that inhibits protoporphyrinogen oxidase .

HY-148285A

Succinyl CoA disodium Succinyl-coenzyme A disodium; S-(Hydrogen succinyl)coenzyme A disodium	Endogenous Metabolite	Metabolic Disease
Succinyl CoA (Succinyl-coenzyme A) disodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA disodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA disodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA disodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl-Coenzyme A sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-137808

Succinyl-Coenzyme A sodium 3 Publications Verification Succinyl-CoA sodium	Structural Classification Natural Products Neurological Disease Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Succinyl CoA (Succinyl-coenzyme A) sodium is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA sodium is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA sodium acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA sodium insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA sodium can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .

HY-113318

Coproporphyrin I	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
Coproporphyrin I is an endogenous metabolite present in Urine and Blood that can be used for the research of Liver Disease and Porphyria .

HY-148285

Succinyl CoA Succinyl-coenzyme A; S-(Hydrogen succinyl)coenzyme A	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite
Succinyl CoA (Succinyl-coenzyme A) is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .

Cat. No.	Product Name	Chemical Structure

HY-W653982

Coproporphyrin I-15N4
Coproporphyrin I- ¹⁵N₄ is a ¹⁵N-labeled Coproporphyrin I (HY-113318). Coproporphyrin I is an endogenous metabolite present in urine and blood that can be used for the research of liver disease and porphyria .

Cat. No.	Product Name		Classification

HY-132610A

Givosiran sodium 1 Publications Verification ALN-AS1 sodium		siRNAs siRNA drugs
Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP) .

HY-132610

Givosiran 1 Publications Verification ALN-AS1		siRNAs siRNA drugs
Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP) .

HY-150151A

GalNac-siRNA negative control (21nt)		siRNAs siRNA drugs
GalNac-siRNA negative control (21nt) is the negative control form of GalNac-siRNA. GalNac-siRNA is an Asialoglycoprotein receptor (ASGPR)-targeted inhibitor conjugate. GalNac-siRNA is promising for research of hereditary transthyretin amyloidosis, acute hepatic porphyria, hemophilia and hypercholesterolemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Porphyria

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products